Skip to Content
Patient Information Leaflets (PILs)

These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD).

The BAD has been awarded The Information Standard certification for the process it employs to develop information products aimed at the general public, which include PILs, Sun Awareness Campaign materials, and other information products.

The BAD shall hold responsibility for the accuracy of the information published, and neither the scheme operator nor the scheme owner shall have any responsibility for costs, losses, or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of the BAD.

Please note:

  1. There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
  2. The offer to provide details of source materials used to inform the British Association of Dermatologists' PILs is for instances where the advice provided in the PILs does not reflect local practice and therefore evidence supporting said advice needs to be produced. It is not an offer to conduct literature searches or supply bibilographic materials for your own research.

For the latest BAD advice on Covid-19 for patients, please check the News and Media section of the website. Find this here. Our information for healthcare professionals is here.

Psoriasis - treatment for moderate or severe psoriasis

Treatment options include:

  1. Phototherapy. Ultraviolet light can be used in several different ways to treat psoriasis.
  2. Treatments with a variety of tablets.
  3. Treatments with a variety of injections.

Tablets or injections to treat psoriasis can be very effective but can also have potentially severe side effects.  They are usually started by a dermatologist, and some can only be prescribed from a hospital because:

  • They require regular clinical assessments and blood tests.
  • Most have the potential to interfere with other medicines.
  • Female patients should not become pregnant whilst on some of the tablets or injections used to treat psoriasis. Additionally, it is important that male patients taking some of these tablets should not father a child. These pregnancy issues may apply for some time after stopping the tablets. 

Treatments with tablets or injections tend to be used: 

  • When psoriasis has failed to respond to topical treatments or comes back quickly after it has cleared.
  • If the psoriasis is severe.
  • If creams and ointments are difficult to apply at certain sites.
  • If treatment with phototherapy has been unsuccessful 
Back to top